Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
KH-631 by Chengdu Kanghong Pharmaceuticals Group for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
KH-631 is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase I for Wet (Neovascular / Exudative)...